Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH JW SC 735 13th Sep, 2024
Maintain Reduce, TP cut to IDR2,000; roll forward base year to FY25F with lower P/E of 17.2x
Market share deterioration persists
As mentioned in our previous reports, Indonesia local FMCG companies have outperformed foreign companies on several fronts, such as: 1) distribution, 2) advertising, 3) product variety, and 4) pricing strategy. Hence, we believe foreign FMCG companies, including UNVR, may continue to suffer market share erosion. Specifically for UNVR, we opine that previous management’s (which was at the helm of the company from 2014 to 2022) modifications to the sales team structure may have caused loss of talent. Moreover, the same management materially increased the number of third-party distributors, likely leading to higher levels of inventory. More importantly, we believe that UNVR HQ’s focus on margins likely came at the expense of market share; and, coupled with the royalty structure and relatively slow decision-making process also likely led to some inefficiencies. Going forward, with a new management team now in place, we believe it will take time to turn around the business, and we note that strategies such as price cuts and promotions may not yield results quickly, as local competitors may respond to counter these accordingly (read our previous report).
Cost-cutting programs may cause higher staff turnover
With Unilever PLC (ULVR LN, Not rated) having announced that it would cut jobs globally (link), we believe its Indonesia operations under UNVR might also face similar restructuring. We believe this situation, if materializes, may cause higher staff turnover in 2H24F, which could negatively affect sales performance. That said, if this strategy is executed carefully, we expect UNVR to gain from long-term benefits, such as creating a leaner organizational structure and at the same time retaining its best talents, which could then spur productivity.
Maintain Reduce; TP lowered to IDR2,000, implying 8% downside
We cut FY24F/FY25F/FY26F EPS by 10%/16%/17% due to market share erosion as well as relatively ineffective price cuts and A&P strategy. We maintain our Reduce call with a lower TP of IDR2,000 (from IDR2,670); we roll forward our base year to FY25F with a lower target P/E of 17.2x (-2.5SD to its three-year mean). Currently, the stock is trading at 18.9x FY25F P/E (EPS: IDR115.8).
Year-end 31 Dec | FY23 | FY24F | FY25F | FY26F | |||
Currency (IDR) | Actual | Old | New | Old | New | Old | New |
Revenue (bn) | 38,611 | 39,898 | 37,488 | 40,640 | 36,858 | 41,601 | 37,735 |
Reported net profit (bn) | 4,801 | 5,080 | 4,593 | 5,284 | 4,418 | 5,380 | 4,448 |
Normalised net profit (bn) | 4,801 | 5,080 | 4,593 | 5,284 | 4,418 | 5,380 | 4,448 |
FD normalised EPS | 125.84 | 133.15 | 120.40 | 138.50 | 115.80 | 141.03 | 116.59 |
FD norm. EPS growth (%) | -10.4 | 5.8 | -4.3 | 4.0 | -3.8 | 1.8 | 0.7 |
FD normalised P/E (x) | 17.4 | – | 18.2 | – | 18.9 | – | 18.8 |
EV/EBITDA (x) | 12.3 | – | 12.7 | – | 13.0 | – | 13.0 |
Price/book (x) | 24.7 | – | 24.4 | – | 24.4 | – | 24.4 |
Dividend yield (%) | 5.7 | – | 5.4 | – | 5.3 | – | 5.3 |
ROE (%) | 130.1 | 149.1 | 134.9 | 153.9 | 128.9 | 156.8 | 129.8 |
Net debt/equity (%) | net cash | net cash | net cash | net cash | net cash | net cash | net cash |
Income statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
Revenue | 41,219 | 38,611 | 37,488 | 36,858 | 37,735 | ||||||||||||||
Cost of goods sold | -22,154 | -19,417 | -18,943 | -18,651 | -19,024 | ||||||||||||||
Gross profit | 19,065 | 19,195 | 18,546 | 18,208 | 18,711 | ||||||||||||||
SG&A | -11,995 | -12,915 | -12,584 | -12,474 | -12,938 | ||||||||||||||
Employee share expense | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Operating profit | 7,070 | 6,279 | 5,962 | 5,734 | 5,772 | ||||||||||||||
EBITDA | 7,881 | 6,683 | 6,526 | 6,380 | 6,377 | ||||||||||||||
Depreciation | -811 | -404 | -564 | -646 | -605 | ||||||||||||||
Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
EBIT | 7,070 | 6,279 | 5,962 | 5,734 | 5,772 | ||||||||||||||
Net interest expense | -84 | -77 | 3 | 4 | 4 | ||||||||||||||
Associates & JCEs | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other income | -1 | 0 | 0 | 0 | 0 | ||||||||||||||
Earnings before tax | 6,985 | 6,202 | 5,965 | 5,737 | 5,776 | ||||||||||||||
Income tax | -1,629 | -1,401 | -1,372 | -1,320 | -1,329 | ||||||||||||||
Net profit after tax | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Minority interests | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Normalised NPAT | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Extraordinary items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Reported NPAT | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Dividends | -5,341 | -4,753 | -4,547 | -4,418 | -4,448 | ||||||||||||||
Transfer to reserves | 15 | 48 | 46 | 0 | 0 | ||||||||||||||
Valuations and ratios | |||||||||||||||||||
Reported P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
Normalised P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
FD normalised P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
Dividend yield (%) | 6.4 | 5.7 | 5.4 | 5.3 | 5.3 | ||||||||||||||
Price/cashflow (x) | 10.9 | 12.9 | 19.0 | 18.5 | 18.4 | ||||||||||||||
Price/book (x) | 20.9 | 24.7 | 24.4 | 24.4 | 24.4 | ||||||||||||||
EV/EBITDA (x) | 10.6 | 12.3 | 12.7 | 13.0 | 13.0 | ||||||||||||||
EV/EBIT (x) | 11.8 | 13.1 | 13.9 | 14.5 | 14.3 | ||||||||||||||
Gross margin (%) | 46.3 | 49.7 | 49.5 | 49.4 | 49.6 | ||||||||||||||
EBITDA margin (%) | 19.1 | 17.3 | 17.4 | 17.3 | 16.9 | ||||||||||||||
EBIT margin (%) | 17.2 | 16.3 | 15.9 | 15.6 | 15.3 | ||||||||||||||
Net margin (%) | 13.0 | 12.4 | 12.3 | 12.0 | 11.8 | ||||||||||||||
Effective tax rate (%) | 23.3 | 22.6 | 23.0 | 23.0 | 23.0 | ||||||||||||||
Dividend payout (%) | 99.7 | 99.0 | 99.0 | 100.0 | 100.0 | ||||||||||||||
ROE (%) | 128.8 | 130.1 | 134.9 | 128.9 | 129.8 | ||||||||||||||
ROA (pretax %) | 38.7 | 37.5 | 38.4 | 37.7 | 39.2 | ||||||||||||||
Growth (%) | |||||||||||||||||||
Revenue | 4.2 | -6.3 | -2.9 | -1.7 | 2.4 | ||||||||||||||
EBITDA | -6.6 | -15.2 | -2.4 | -2.2 | 0.0 | ||||||||||||||
Normalised EPS | -7.0 | -10.4 | -4.3 | -3.8 | 0.7 | ||||||||||||||
Normalised FDEPS | -7.0 | -10.4 | -4.3 | -3.8 | 0.7 | ||||||||||||||
Source: Company data, Nomura estimates |
Cashflow statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
EBITDA | 7,881 | 6,683 | 6,526 | 6,380 | 6,377 | ||||||||||||||
Change in working capital | 1,499 | 1,275 | -751 | -550 | -502 | ||||||||||||||
Other operating cashflow | -1,714 | -1,478 | -1,369 | -1,316 | -1,325 | ||||||||||||||
Cashflow from operations | 7,667 | 6,480 | 4,405 | 4,514 | 4,551 | ||||||||||||||
Capital expenditure | -245 | -178 | -250 | -250 | 100 | ||||||||||||||
Free cashflow | 7,421 | 6,302 | 4,155 | 4,264 | 4,651 | ||||||||||||||
Reduction in investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Net acquisitions | 0 | 0 | 0 | 0 | |||||||||||||||
Dec in other LT assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Inc in other LT liabilities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Adjustments | 110 | 53 | 56 | -82 | -7 | ||||||||||||||
CF after investing acts | 7,531 | 6,354 | 4,212 | 4,182 | 4,644 | ||||||||||||||
Cash dividends | -5,341 | -4,753 | -4,547 | -4,418 | -4,448 | ||||||||||||||
Equity issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Debt issue | -1,250 | -600 | 0 | 0 | 0 | ||||||||||||||
Convertible debt issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Others | -763 | -484 | 71 | -3 | 5 | ||||||||||||||
CF from financial acts | -7,354 | -5,837 | -4,477 | -4,420 | -4,443 | ||||||||||||||
Net cashflow | 178 | 518 | -265 | -239 | 201 | ||||||||||||||
Beginning cash | 325 | 503 | 1,021 | 756 | 517 | ||||||||||||||
Ending cash | 503 | 1,021 | 756 | 517 | 718 | ||||||||||||||
Ending net debt | 97 | -1,021 | -756 | -517 | -718 | ||||||||||||||
Balance sheet (IDRbn) | |||||||||||||||||||
As at 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
Cash & equivalents | 503 | 1,021 | 756 | 517 | 718 | ||||||||||||||
Marketable securities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts receivable | 4,416 | 2,719 | 2,909 | 2,860 | 2,928 | ||||||||||||||
Inventories | 2,625 | 2,422 | 2,363 | 2,326 | 2,373 | ||||||||||||||
Other current assets | 24 | 30 | 29 | 29 | 29 | ||||||||||||||
Total current assets | 7,568 | 6,192 | 6,057 | 5,732 | 6,049 | ||||||||||||||
LT investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Fixed assets | 9,536 | 9,311 | 8,997 | 8,601 | 7,896 | ||||||||||||||
Goodwill | 62 | 62 | 62 | 62 | 62 | ||||||||||||||
Other intangible assets | 447 | 399 | 443 | 535 | 528 | ||||||||||||||
Other LT assets | 705 | 700 | 600 | 590 | 604 | ||||||||||||||
Total assets | 18,318 | 16,664 | 16,159 | 15,520 | 15,139 | ||||||||||||||
Short-term debt | 600 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts payable | 4,700 | 4,064 | 4,209 | 3,730 | 3,459 | ||||||||||||||
Other current liabilities | 7,142 | 7,160 | 6,393 | 6,236 | 6,121 | ||||||||||||||
Total current liabilities | 12,442 | 11,224 | 10,602 | 9,966 | 9,580 | ||||||||||||||
Long-term debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Convertible debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT liabilities | 1,879 | 2,059 | 2,129 | 2,127 | 2,131 | ||||||||||||||
Total liabilities | 14,321 | 13,283 | 12,732 | 12,093 | 11,711 | ||||||||||||||
Minority interest | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred stock | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Common stock | 76 | 76 | 76 | 76 | 76 | ||||||||||||||
Retained earnings | 3,825 | 3,209 | 3,255 | 3,255 | 3,255 | ||||||||||||||
Proposed dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other equity and reserves | 96 | 96 | 96 | 96 | 96 | ||||||||||||||
Total shareholders' equity | 3,997 | 3,381 | 3,427 | 3,427 | 3,427 | ||||||||||||||
Total equity & liabilities | 18,318 | 16,664 | 16,159 | 15,520 | 15,139 | ||||||||||||||
Liquidity (x) | |||||||||||||||||||
Current ratio | 0.61 | 0.55 | 0.57 | 0.58 | 0.63 | ||||||||||||||
Interest cover | 84.6 | 81.1 | – | – | – | ||||||||||||||
Leverage | |||||||||||||||||||
Net debt/EBITDA (x) | 0.01 | net cash | net cash | net cash | net cash | ||||||||||||||
Net debt/equity (%) | 2.4 | net cash | net cash | net cash | net cash | ||||||||||||||
Per share | |||||||||||||||||||
Reported EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
Norm EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
FD norm EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
BVPS (IDR) | 104.78 | 88.63 | 89.83 | 89.83 | 89.83 | ||||||||||||||
DPS (IDR) | 140.00 | 124.59 | 119.19 | 115.80 | 116.59 | ||||||||||||||
Activity (days) | |||||||||||||||||||
Days receivable | 41.0 | 33.7 | 27.5 | 28.6 | 28.0 | ||||||||||||||
Days inventory | 41.8 | 47.4 | 46.2 | 45.9 | 45.1 | ||||||||||||||
Days payable | 76.4 | 82.4 | 79.9 | 77.7 | 69.0 | ||||||||||||||
Cash cycle | 6.5 | -1.2 | -6.2 | -3.2 | 4.1 | ||||||||||||||
Source: Company data, Nomura estimates |
Rating Remains | Reduce |
Target price Reduced from IDR 2,670 | IDR 2,000 |
Closing price 11 September 2024 | IDR 2,190 |
Implied upside | -8.7% |
Market Cap (USD mn) | 5,427.0 |
ADT (USD mn) | 2.9 |
M cap (USDmn) | 5,427.0 |
Free float (%) | 15.0 |
3-mth ADT (USDmn) | 2.9 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -11.0 | -28.4 | -40.0 |
Absolute (USD) | -7.9 | -24.3 | -40.3 |
Rel to Jakarta Stock Exchange Composite Index | -17.9 | -41.6 | -51.5 |
Sandy Ham (sandy.ham@verdhana.id),
Jody Wijaya (jody.wijaya@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)